NUVATION BIO INC CLASS A (NUVB)
Health Care · biotechnology · NYSE
Nuvation Bio is a clinical-stage oncology firm advancing a portfolio of targeted small-molecule therapies for patients with solid tumors, highlighted by its ROS1-positive NSCLC treatment, IBTROZI.
What NUVATION BIO INC CLASS A does
Nuvation Bio is a global oncology company focused on developing novel small-molecule therapies to address challenging cancers. The company's lead product is IBTROZI (taletrectinib), a ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Its pipeline also includes safusidenib, a brain-penetrant mIDH1 inhibitor currently in clinical development for IDH1-mutant glioma.
Themes: oncology drug development, ROS1+ NSCLC, IDH1-mutant glioma, small molecule inhibitors, targeted cancer therapy
Fundamentals
- Price$4.95 as of 2026-10-08 close
- Market cap$1.7B as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+33.1% 2025-10-08 close $3.72 → 2026-10-08 close $4.95
- P/En/a negative earnings
- Net margin-325.3% FY2025, SEC XBRL
- Gross margin+10.1% FY2024, SEC XBRL
- ROE-66.9% FY2025, SEC XBRL
- Debt / equity1.63 as of 2026-09-03
- Revenue growth (YoY)+1083.6% as of 2026-09-03
- Beta1.45 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How NUVB compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginbottom 10% 189 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NUVB is not currently in any published Top 10 list. Its scores are below.
Top 10 score
37.1 #1264 of 1,398 scored · #142 of 155 in Health Care
Growth 100th (revenue growth year over year 1083.6%) and trend 49th (over the past 12 months this stock beat the market by 73.5 percentage points); weakest is profitability (2nd, return on equity -66.9%, operating margin -338.7%).
Scores as of 25 Sep 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4. NUVB was not in the scored universe at the latest run on 8 Oct 2026, so these scores are its last ones.
How NUVATION BIO INC CLASS A looks technically
NUVATION BIO INC CLASS A (NUVB) is trading 14.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 42 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30). It made a new 20-day low about 2 trading days ago. It is 49.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 14.6% below its 200-day average, the long-term trend line — a long-term downtrend | -14.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.21 | $6.21 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.80 | $5.80 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 6.26. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 42 trading days ago — a "golden cross", a bullish long-term signal | 42 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control | 27.7 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30) | 28.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($4.63 to $6.26) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 19.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.75 | $9.75 |
|---|---|---|
| From the 52-week high | it is 49.2% below its 52-week high (its highest price of the past year) | -49.2% |
| Above the 52-week low | it is 47.3% above its 52-week low (its lowest price of the past year) | +47.3% |
| Below the 52-week high | it is 49.2% below its highest point of the past year | 49.2% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $15.23 (set on 2021-05-26) | $15.23 |
| Given back of the 52-week move | over the past year its closes ranged ($3.41 to $9.54), and it has given back well over two thirds of its rise from last year’s low — 75% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.56 to $5.75. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 74.9% |
| From the all-time high | it is 67.5% below its all-time high | -67.5% |
| Nearest price level | it is trading 3.9% below a resistance level at $5.14 — a price it turned at twice since 2026-01-30, most recently on 2026-05-06. Since 2024-10-08 it has 10 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.9% |
| All-time low | its lowest closing price on record is $0.95 (set on 2023-10-31) | $0.95 |
| Above the all-time low | it is 421.1% above its all-time low | +421.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 90% of the past ~6 months) | 90th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2999 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2999 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.78 and $6.42 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.78 – $5.60 – $6.42 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 2.8 daily ranges below its 200-day average price (14.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.81× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.8% since the prior reading | -0.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.05 toward buy |
Candlestick patterns
1
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.2% |
|---|---|---|
| Gap filled | a 3.4% gap up opened on 2026-09-30 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.2 percentage points (the stock lost 25.1% while the market gained 1.0%) | -26.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.5 percentage points (the stock lost 15.7% while the market gained 3.8%) | -19.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 6.2 percentage points (the stock gained 11.2% while the market gained 17.5%) | -6.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 18.1 percentage points (the stock gained 33.1% while the market gained 15.0%) | +18.1% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 23% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.3% of the share price. | -23.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $5.68 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -12.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $6.11 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -18.9% |
Price levels it has turned at before
NUVB last closed at $4.95 on 2026-10-08. Since 2024-10-08 it has turned at 10 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.14 | Resistance | 3.9% above the last close | turned there twice · 2026-01-30 to 2026-05-06 |
| $5.32 | Resistance | 7.5% above the last close | turned there four times · 2026-02-23 to 2026-07-17 |
| $5.59 | Resistance | 12.9% above the last close | turned there twice · 2025-10-29 to 2026-09-15 |
| $4.09 | Support | 17.4% below the last close | turned there five times · 2025-09-05 to 2026-05-19 |
| $3.94 | Support | 20.5% below the last close | turned there twice · 2025-09-30 to 2025-11-04 |
| $3.46 | Support | 30.1% below the last close | turned there twice · 2025-01-07 to 2025-09-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $6.26.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $3.10 and $4.31 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $6.26.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.45 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$13.00 range $7.00 – $21.00; median $12.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NUVB
- Consensus EPS estimate-$0.09 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 from -$0.09, on 2026-08-30, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the commercial success of IBTROZI (taletrectinib) and the clinical success of pipeline assets like safusidenib.","Significant history of operating losses and continued requirement for capital to fund clinical trials and commercialization.","Risks associated with regulatory approvals, intellectual property protection, and managing complex global partnerships."]
What changed in the latest 10-Q
AI-assisted comparison of NUVB's 10-Q filed 2026-05-04 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
- Added:
- In January 2026, we announced a partnership with Eisai Co., Ltd. ("Eisai") to commercialize taletrectinib in Europe and other territories outside the U.S., China and Japan.
- In March 2026, we announced that the European Medicines Agency had validated the Marketing Authorisation Application ("MAA") for taletrectinib for the treatment of advanced ROS1+ NSCLC.
- On February 10, 2026, the outstanding warrants to purchase Class A Common stock expired and were delisted pursuant to a Form 25 filed by The New York Stock Exchange.
- In February 2026, we announced a protocol amendment to SIGMA study for safusidenib in IDH1-mutant glioma, which converted the study from a Phase 2 to a Phase 3 study.
- In March 2026, the Company announced that new data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22, 2026, in San Diego, California.
- In March 2026, the Company has been named to Fast Company's 2026 list of the Most Innovative Companies—ranked #9 in the Medicines, Therapeutics, and Pharmaceuticals category.
- In March 2026, the Company appointed Stephen Dang, Ph.D., as Chief Legal Officer. Dr. Dang brings over 18 years of experience in the biopharmaceutical industry across all stages of the drug product life cycle.
- In April 2026, the Company has amended its existing exclusive license agreement for safusidenib with Daiichi Sankyo to include Japan in the territory rights licensed to the Company, effectively securing exclusive global safusidenib development and commercialization rights for the Company.
- Removed:
- Taletrectinib was previously granted Breakthrough Therapy Designations by both the U.S. FDA and China's National Medical Products Administration ("NMPA") for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC.
- Our clinical-stage pipeline includes differentiated, novel oncology product candidates that have been generated from our proprietary drug discovery and development programs or acquired through business development activities:
- Safusidenib is being evaluated in the G203 study, which is currently a randomized phase 2 study for the maintenance treatment of high grade IDH1-mutant glioma with safusidenib against placebo. Following alignment with FDA, a protocol amendment is in progress to finalize G203 as a global Phase 3 study by increasing the study size to support potential regulatory approvals.
- NUV-1511 is our first clinical-stage drug-drug conjugate ("DDC"), which fuses a targeting agent to a widely used chemotherapy agent. NUV-1511 is being evaluated in a Phase 1/2 study in patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu® and/or Trodelvy® per approved U.S. FDA labeling, human epidermal growth factor receptor 2-negative ("HER2-") metastatic breast cancer, metastatic castration-resistant prostate cancer ("mCRPC"), advanced pancreatic cancer, and platinum-resistant ovarian cancer ("PROC"). We expect to provide an update from the Phase 1/2 dose escalation study of NUV-1511 in the second half of 2025.
- NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal ("BET") inhibitor that inhibits BRD4. As previously announced, we are evaluating next steps for the NUV-868 program, including further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients.
- In September 2025, additional data from our pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib was presented at the 2025 World Conference on Lung Cancer.
- In September 2025, Japan's MHLW approved IBTROZI for the treatment of adult patients with ROS1+ unresectable, advanced and/or recurrent NSCLC.
- In September 2025, we announced enrollment of the first patient in the taletrectinib Phase 3 TRUST-IV study for the adjuvant treatment of patients with resected ROS1+ NSCLC.
- In October 2025, we announced enrollment of the first patient in the safusidenib G203 study for the maintenance treatment of high-grade IDH1-mutant glioma.
- Reworded:
- FDA abbreviation changed from full "U.S. Food and Drug Administration ("FDA")" in older filing to "FDA" in newer filing (2026-05-04).
- Japan's regulatory body reference changed from "Ministry of Health, Labour, and Welfare ("MHLW")" in older filing to "Japan's MHLW" in newer filing (2026-05-04).
- China's regulatory body reference changed from "National Medical Products Administration ("NMPA")" in older filing to "China's NMPA" in newer filing (2026-05-04).
- Japan's partner reference changed from "Nippon Kayaku Co., Ltd" in older filing to "our partner NK" in newer filing (2026-05-04).
- China's partner reference changed from "Innovent Biologics (Suzhou) Co. Ltd. ("Innovent")" in older filing to "our partner Innovent" in newer filing (2026-05-04).
- Breakthrough Therapy Designation text changed from "for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC" in older filing to "for the treatment of both TKI-naïve and TKI-pretreated disease patients with locally advanced or metastatic ROS1+ NSCLC" in newer filing (2026-05-04).
- Safusidenib study name and description changed from "G203 study" with "randomized phase 2 study" in older filing to "SIGMA study" with "randomized Phase 3 study" in newer filing (2026-05-04).
- Revenue description changed from "including upfront license fees" in older filing to "including upfront license fees and milestone payments" in newer filing (2026-05-04).
- Accumulated deficit changed from "$1,078.8 million" as of September 30, 2025 in older filing to "$1,110.0 million" as of March 31, 2026 in newer filing (2026-05-04).
- Notes:
- The newer filing text appears truncated at the end of the Financial Overview section, potentially affecting completeness of comparison.
- The older filing text also appears truncated, ending mid-word at "thir" in the final paragraph.
- Two recent developments sections exist in the documents with different content organization and dating.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($709240) — 1 selling insider
- Last 180 days · read to 2026-10-041 buy ($118250) · 6 sells ($3M) — 1 buying, 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-19. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NUVB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NUVB as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 92,819,981
- Reported value $527,217,493
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NUVB's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NUVB had 58,173,586 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
NUVB had 16.6% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.89 days to cover at the same settlement.
- Reported short interest (shares) 58,173,586
- Short interest (% of shares outstanding) 16.6%
- Prior settlement (shares) 54,264,998
- Reported change 7.2%
- Days to cover (reported) 10.89
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Pfizer (PFE)
- Novartis (NVS)
- AstraZeneca (AZN)
- Blueprint Medicines (BPMC)
- Turning Point Therapeutics (Bristol Myers Squibb - BMY)
- Agios Pharmaceuticals (AGIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NUVB vs…
NUVATION BIO INC CLASS A is found in…
NUVB ranks in…
Frequently asked questions
What does NUVATION BIO INC CLASS A (NUVB) do?
Nuvation Bio is a global oncology company focused on developing novel small-molecule therapies to address challenging cancers. The company's lead product is IBTROZI (taletrectinib), a ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Its pipeline also includes safusidenib, a brain-penetrant mIDH1 inhibitor currently in clinical development for IDH1-mutant glioma.
What sector is NUVATION BIO INC CLASS A (NUVB) in?
NUVATION BIO INC CLASS A (NUVB) is classified in the Health Care sector. Its industry is biotechnology. It trades on NYSE.
Who are NUVATION BIO INC CLASS A's (NUVB) competitors?
Notable peers of NUVATION BIO INC CLASS A (NUVB) include Pfizer, Novartis, AstraZeneca, Blueprint Medicines and Turning Point Therapeutics (Bristol Myers Squibb - BMY). This peer set is informational only — not financial advice.
Is NUVATION BIO INC CLASS A (NUVB) overbought or oversold right now?
NUVATION BIO INC CLASS A (NUVB) is currently in oversold territory (its 14-day RSI is 29, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NUVB come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.